Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Chief Medical Officer and SVP | March 14, 2019 | March 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date March 14, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2019-12-31 | Direct | 50,000 |
Reported balance
After 2019-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-14 · Grant · Acquired 50,000 · Balance 50,000 F1: All of the option shares will vest and become exercisable upon the closing of a Change of Control transaction (as defined in Mr. Sarlis' stock option grant notice), provided that the Reporting Person remains in continuous service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the option shares will vest and become exercisable upon the closing of a Change of Control transaction (as defined in Mr. Sarlis' stock option grant notice), provided that the Reporting Person remains in continuous service with the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2019 Filed Mar 18, 2019 19:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008204 · doc4.xml · derivative · entry 1 Sarlis Nicholas J. · CIK 0001724151 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-12-31 F1 · derivative.exercise_date: All of the option shares will vest and become exercisable upon the closing of a Change of Control transaction (as defined in Mr. Sarlis' stock option grant notice), provided that the Reporting Person remains in continuous service with the Issuer on the vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 19:57 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020014 · doc4.xml · derivative · entry 1 Sarlis Nicholas J. · CIK 0001724151 · Chief Medical Officer and SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.